Abstract
Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an international "public health emergency" in 2016 by the World Health Organization (WHO). Until this time, ZIKV was considered to induce only mild illness, but it has now been established as the cause of severe clinical manifestations, including fetal anomalies, neurological problems, and autoimmune disorders. Infection during pregnancy can cause congenital brain abnormalities, including microcephaly and neurological degeneration, and in other cases, Guillain-Barré syndrome, making infections with ZIKV a substantial public health concern. Genomic and molecular investigations are underway to investigate ZIKV pathology and its recent enhanced pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics. This review describes progress in the design and development of various anti-ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers, neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-associated disease, we need to make rapid progress in developing novel therapies that work effectually to inhibit ZIKV.
| Original language | English (US) |
|---|---|
| Article number | 1469 |
| Journal | Frontiers in Microbiology |
| Volume | 8 |
| Issue number | AUG |
| DOIs | |
| State | Published - Aug 3 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- Drugs
- Guillain-Barré Syndrome
- Microcephaly
- Therapies
- Zika virus
ASJC Scopus subject areas
- Microbiology
- Microbiology (medical)
Cite this
Advances in developing therapies to combat zika virus : Current knowledge and future perspectives. / Munjal, Ashok; Khandia, Rekha; Dhama, Kuldeep; Sachan, Swati; Karthik, Kumaragurubaran; Tiwari, Ruchi; Malik, Yashpal S.; Kumar, Deepak; Singh, Raj K.; Iqbal, Hafiz M.N.; Joshi, Sunil.
In: Frontiers in Microbiology, Vol. 8, No. AUG, 1469, 03.08.2017.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Advances in developing therapies to combat zika virus
T2 - Current knowledge and future perspectives
AU - Munjal, Ashok
AU - Khandia, Rekha
AU - Dhama, Kuldeep
AU - Sachan, Swati
AU - Karthik, Kumaragurubaran
AU - Tiwari, Ruchi
AU - Malik, Yashpal S.
AU - Kumar, Deepak
AU - Singh, Raj K.
AU - Iqbal, Hafiz M.N.
AU - Joshi, Sunil
PY - 2017/8/3
Y1 - 2017/8/3
N2 - Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an international "public health emergency" in 2016 by the World Health Organization (WHO). Until this time, ZIKV was considered to induce only mild illness, but it has now been established as the cause of severe clinical manifestations, including fetal anomalies, neurological problems, and autoimmune disorders. Infection during pregnancy can cause congenital brain abnormalities, including microcephaly and neurological degeneration, and in other cases, Guillain-Barré syndrome, making infections with ZIKV a substantial public health concern. Genomic and molecular investigations are underway to investigate ZIKV pathology and its recent enhanced pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics. This review describes progress in the design and development of various anti-ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers, neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-associated disease, we need to make rapid progress in developing novel therapies that work effectually to inhibit ZIKV.
AB - Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an international "public health emergency" in 2016 by the World Health Organization (WHO). Until this time, ZIKV was considered to induce only mild illness, but it has now been established as the cause of severe clinical manifestations, including fetal anomalies, neurological problems, and autoimmune disorders. Infection during pregnancy can cause congenital brain abnormalities, including microcephaly and neurological degeneration, and in other cases, Guillain-Barré syndrome, making infections with ZIKV a substantial public health concern. Genomic and molecular investigations are underway to investigate ZIKV pathology and its recent enhanced pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics. This review describes progress in the design and development of various anti-ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers, neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-associated disease, we need to make rapid progress in developing novel therapies that work effectually to inhibit ZIKV.
KW - Drugs
KW - Guillain-Barré Syndrome
KW - Microcephaly
KW - Therapies
KW - Zika virus
UR - http://www.scopus.com/inward/record.url?scp=85026836080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026836080&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2017.01469
DO - 10.3389/fmicb.2017.01469
M3 - Review article
AN - SCOPUS:85026836080
VL - 8
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
SN - 1664-302X
IS - AUG
M1 - 1469
ER -